Brentuximab vedotin in a patient with enteropathy-associated T-cell lymphoma of the small bowel.

As the prognosis of enteropathy-associated T-cell lymphoma is poor, innovative treatment options are called for, such as the anti-CD30 monoclonal antibody-drug conjugate brentuximab vedotin. The patient presented in this report was diagnosed with enteropathy-associated T-cell lymphoma that affected the jejunum. Standard chemotherapy with CHOP induced complete remission, but the disease relapsed within 8 months, with the ileum as the site of relapse. Since further testing revealed CD30 positivity, treatment with brentuximab vedotin was started. After 18 cycles, the treatment had to be discontinued owing to another condition that required surgery, upon which the patient relapsed. However, resumption of brentuximab vedotin therapy restored partial remission within 3 months. [ABSTRACT FROM AUTHOR]